Search results
Showing 46 to 60 of 67 results for epilepsy
Mental health of adults in contact with the criminal justice system (NG66)
This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.
This guideline has been updated and replaced by NICE guideline CG137.
This guideline has been updated and replaced by NICE guideline CG137.
This guidance has been updated and replaced by NICE HealthTech guidance 550.
Antenatal and postnatal mental health: clinical management and service guidance (CG192)
This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers depression, anxiety disorders, eating disorders, drug- and alcohol-use disorders and severe mental illness (such as psychosis, bipolar disorder and schizophrenia). It promotes early detection and good management of mental health problems to improve women’s quality of life during pregnancy and in the year after giving birth.
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)
This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.
Show all sections
Sections for NG252
- Overview
- Designing and commissioning rehabilitation services
- Assessing rehabilitation needs and goal setting
- Rehabilitation planning and delivery
- Information, advice and learning as part of rehabilitation
- Rehabilitation to maintain, improve or support function
- Rehabilitation to support education, work, social and leisure activities, relationships and sex
- Terms used in this guideline
This guideline covers recognising, assessing and treating bipolar disorder (formerly known as manic depression) in children, young people and adults. The recommendations apply to bipolar I, bipolar II, mixed affective and rapid cycling disorders. It aims to improve access to treatment and quality of life in people with bipolar disorder.
Deep brain stimulation for refractory epilepsy in adults (IPG678)
We have moved interventional procedures guidance 678 to become HealthTech guidance 550. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Vagus nerve stimulation for refractory epilepsy in children (IPG50)
We have moved interventional procedures guidance 50 to become HealthTech guidance 25. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)
Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.
Retigabine for the adjunctive treatment of partial onset seizures in epilepsy (TA232)
The guidance has been withdrawn because GlaxoSmithKline has discontinued retigabine (Trobalt) due to limited usage.
MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy (IPG671)
We have moved interventional procedures guidance 671 to become HealthTech guidance 541. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.